Acadia Pharmaceuticals Inc. (ACAD)
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President, Trofinetide Elizabeth Thompson - Executive Vice President, Head of Research and Development Conference Call Participants Ritu Baral - TD Cowen Charles Duncan - Cantor Anish Nikhanj - RBC Capital Markets Joel Beatty - Baird Marc Goodman - Leerink Jeff Hung - Morgan Stanley Keith Tapper - BMO Capital Markets David Hoang - Citigroup Eddie Hickman - Guggenheim Tessa Romero - JPMorgan Operator Good day ladies and gentlemen, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
Acadia Pharmaceuticals: Back In The Buy Zone
Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times FY24 revenue net of cash. An updated analysis around Acadia Pharmaceuticals follows in the paragraphs below.
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
